Biopharmaceutical Contract Manufacturing Market Biopharmaceutical Contract Manufacturing Learn how outsourcing trends in biopharma m ...

The global cell counting market, valued at US$10.82 billion in 2023, is forecasted to grow at a robust CAGR of 7.7%, reaching US$11.12 billion ...

Revenues increased 34% compared to the previous quarter ended September 30, 2024; and exceeded $1 millionReceived CE Mark for LungFit PH® in ...

Genomics, Inc. , a leader in single cell and spatial biology, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided outlook for ...

SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), today reported financial results for the second quarter ended Dec. 31, ...

Researchers have produced a review of chromatography media and purification processes for handling complex and super-large ...

About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...

Core Illumina revenue of $1.1 billion for Q4 2024, up 1% from Q4 2023 on both a reported and constant currency basis; revenue of $4.3 billion for fiscal year 2024, down 2% from fiscal year 2023 on ...

Less than 20 years after the first biopharmaceutical, insulin, was approved, a new generation of products is superseding replacement proteins and enzyme therapies in biotechnology's pipeline.